Advertisement

Topics

DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF

03:30 EDT 13 Jul 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
AMF REGULATED INFORMATIONMontrouge, France, July 13, 2018 Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a cli...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Bioethics
Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...